TRACON Pharmaceuticals (NASDAQ:TCON) CEO Charles Theuer says the enrollment of the 36th patient in its ENVASARC pivotal trial for envafolimab will enable the initial independent data monitoring committee (IDMC) interim efficacy analysis to proceed.
He said this is expected to occur in the fourth quarter of this year.
Theuer noted that TRACON is currently ahead of the enrollment projection that would allow for full accrual of the 160 planned patients dosed with 600 mg of envafolimab before the end of 2023.